Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iobenguane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.84 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.71 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.71 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.71 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.65 |
| ▸ | HTR3B | O95264 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iobenguane SCHEMBL16040804 | 0.98 | CYP1A2 (0.96) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Iobenguane SCHEMBL29722658 | 0.92 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Iobenguane SCHEMBL29435410 | 0.92 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Iobenguane SCHEMBL9798689 | 0.92 | SMN1; SMN2 (1.00) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| SCHEMBL3927834 | 0.81 | HIF1A (0.69) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| SCHEMBL23521033 | 0.78 | GRIN2B (0.74) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Iobenguane I 131 SCHEMBL29431814 | 0.77 | GRIN2B (0.71) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Iobenguane I 123 SCHEMBL29381016 | 0.77 | HTR1A (1.00) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| Hydrochloric Acid SCHEMBL538276 | 0.77 | HTR3E (0.96) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| M-Fluorobenzylguanidine SCHEMBL4335227 | 0.77 | TAAR1 (0.75) | CYP1A2CYP2D6CYP2C19THPORAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 888 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| US-20250345629-A1 | JOINT OPTIMIZATION OF RADIONUCLIDE AND EXTERNAL BEAM RADIOTHERAPY | REFLEXION MEDICAL INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| US-20250152757-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | JUBILANT DRAXIMAGE INC (CA) | 2025-05-15 | — | — | US | claimed |
| EP-4543498-A2 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | Suntec Medical, Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| US-12285501-B2 | Compound targeting norepinephrine transporter | Higuchi, Takahiro (DE) | 2025-04-29 | — | — | US | claimed |
| WO-2025085311-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF KMT2D-DEFICIENT CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | claimed |
| US-20250121100-A1 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | SUNTEC MEDICAL INC (US) | 2025-04-17 | — | — | US | claimed |
| WO-2007008232-A2 | LOCOREGIONAL INTERNAL RADIONUCLIDE ABLATION OF ABNORMAL TISSUES. | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060079463-A1 | Anticancer compositions comprising methenamine | ZHONG HONG J | 2006-04-13 | — | — | US | claimed |
| EP-1552308-A1 | DEMETHYLATED AND/OR OXIDIZED MEMBRANE DNA AND USE THEREOF IN THE DIAGNOSTIC OF AUTOIMMUNE DISEASES | Biotech Tools S.A. (BE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004110361-A2 | ANTICANCER COMPOSITIONS COMPRISING METHENAMINE | ZHONG HONG JI (US) | 2004-12-23 | — | — | WO | claimed |
| WO-2004036219-A1 | DEMETHYLATED AND/OR OXIDIZED MEMBRANE DNA AND USE THEREOF IN THE DIAGNOSTIC OF AUTOIMMUNE DISEASES | BIOTECH TOOLS S.A. (BE) | 2004-04-29 | — | — | WO | claimed |
| US-20040072304-A1 | Demethylated and/or oxidized membrane DNA | HENOT FREDERIC (BE) | 2004-04-15 | — | — | US | claimed |
| US-6544541-B1 | Applying meta-iodobenzylguanidine (MIBG) and pharmaceutically acceptable excipient to a damaged vessel for inhibiting restenosis | CARDIOVASCULAR SOLUTIONS, INC. (CA) | 2003-04-08 | — | — | US | claimed |
| EP-1004321-B1 | STABLE RADIOACTIVE MEDECINE | DAIICHI RADIOISOTOPE LAB (JP) | 2003-02-26 | — | — | EP | claimed |
| US-5019323-A | Radioactive drug | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 1991-05-28 | — | — | US | claimed |
| US-4584187-A | RADIOIODINATED METAIODOBENZYL GUANIDINE;DIAGNOSS AND TREASTMENT OF HEART, ADRENAL MEDULLA, TUMORS | WIELAND DONALD M | 1986-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | HPGDS, AIPL1, PON1 | SLC6A2 74/4885CYP1A2 3845/4885CYP2D6 1452/4885 |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | SLC6A2 1200/4885CYP1A2 3032/4885CYP2D6 2041/4885 |
| US-12285501-B2 | Compound targeting norepinephrine transporter | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885CYP1A2 375/4885CYP2D6 213/4885 |
| US-20250121100-A1 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | ABCB4, C5, APOB | SLC6A2 811/4885CYP1A2 2937/4885CYP2D6 2126/4885 |
| US-20250152757-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | GCG, VHL, SHBG | SLC6A2 487/4885CYP1A2 1724/4885CYP2D6 298/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | SLC6A2 4479/4885CYP1A2 2660/4885CYP2D6 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.